PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

PTC Therapeutics (NASDAQ: PTCT) announced inducement equity grants approved Nov. 24, 2025, to 15 new employees under Nasdaq Listing Rule 5635(c)(4).

The company approved non-statutory stock options to purchase an aggregate of 2,000 shares and 8,200 restricted stock units (RSUs). Options have an exercise price of $79.83 (closing price on Nov. 24, 2025), a 10-year term, and vest over four years: 25% at first anniversary then 6.25% each subsequent three months. RSUs vest over four years with 25% on each annual anniversary. Grants were approved by the Compensation Committee and issued as inducements material to each hire's acceptance of employment.

News Market Reaction

-7.90%

1 alert

-7.90% News Effect

On the day this news was published, PTCT declined 7.90%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Current price: $75.44 Stock options granted: 2,000 shares RSUs granted: 8,200 units +5 more

8 metrics

Current price $75.44 Pre-news trading level vs 200-day MA and 52-week range

Stock options granted 2,000 shares Non-statutory options as inducement awards to new hires

RSUs granted 8,200 units Restricted stock units for inducement grants

New employees 15 employees Recipients of inducement equity awards

Exercise price $79.83 per share Option strike set at Nov. 24, 2025 closing price

Option term 10 years Life of inducement stock options

Vesting schedule 4 years Options and RSUs vest over four years with 25% first year

Quarterly vesting rate 6.25% Post-first-year quarterly vesting for stock options

Market Reality Check

Price: $75.25 Vol: Volume 703,886 vs 20-day ...

low vol

$75.25 Last Close

Volume Volume 703,886 vs 20-day average 2,267,500 ahead of this filing-focused news. low

Technical Shares traded above the 200-day MA, with price 75.44 vs 200-day MA 55.75.

Peers on Argus

Before this inducement grant news, PTCT was modestly higher while key biotech pe...

Before this inducement grant news, PTCT was modestly higher while key biotech peers showed mixed but generally positive moves (e.g., CRSP, TGTX, KRYS up; MRUS slightly down), and no sector-wide momentum signal was flagged.

Historical Context

5 past events · Latest: Dec 01 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 01	Inducement grants	Neutral	-7.9%	Inducement stock options and RSUs granted to 15 new employees.
Nov 20	R&D day update	Neutral	+1.1%	Announcement of Dec. 2 R&D Day and platform update presentations.
Nov 04	Q3 2025 earnings	Positive	-0.3%	Profitable Q3 with $211.0M revenue and narrowed full-year guidance.
Oct 31	Investor conferences	Neutral	+0.3%	Participation in three upcoming healthcare investor conferences with webcasts.
Oct 27	Inducement grants	Neutral	+0.6%	Small inducement option and RSU grants for two new employees.

Pattern Detected

Recent news has generally produced modest price moves, with one prior inducement grant announcement coinciding with a larger one-day decline and earnings news seeing a small negative reaction despite profitability.

Recent Company History

Over the last few months, PTC reported multiple routine updates along with stronger fundamentals. Q3 2025 results on Nov 4 showed revenue of $211.0M and net income of $15.9M, marking profitability and updated 2025 revenue guidance of $750–$800M. Other items included conference participation and an R&D Day set for Dec 2, 2025. The company also issued prior inducement equity grants on Oct 23, 2025. Today’s inducement grants follow that same pattern of small, hiring-related equity awards.

Market Pulse Summary

The stock moved -7.9% in the session following this news. A negative reaction despite the routine na...

Analysis

The stock moved -7.9% in the session following this news. A negative reaction despite the routine nature of these inducement awards would be consistent with past instances where solid fundamentals did not prevent weakness, such as the Q3 2025 earnings reaction of -0.31%. The grants are small (2,000 options and 8,200 RSUs) and similar to an inducement filing on Oct 23, 2025. Any sharp downside move could reflect broader positioning or sensitivity to incremental equity issuance rather than the mechanics of this specific grant.

Key Terms

non-statutory stock options, restricted stock units ("RSUs"), Nasdaq Listing Rule 5635(c)(4)

3 terms

non-statutory stock options financial

"the company approved non-statutory stock options to purchase an aggregate of 2,000 shares"

Non-statutory stock options are a type of reward that companies give to employees, allowing them to buy company shares at a set price within a certain period. Unlike formal or government-approved plans, these options are more flexible but may have different tax implications. For investors, they can influence a company's stock price and financial health, making them an important factor to consider.

restricted stock units ("RSUs") financial

"and 8,200 restricted stock units ("RSUs"), each representing the right to receive one share"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Nasdaq Listing Rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. Not financial advice.

WARREN, N.J., Dec. 1, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 24, 2025 , the company approved non-statutory stock options to purchase an aggregate of 2,000 shares of its common stock and 8,200 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 15 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.

The inducement grants were approved by PTC's Compensation Committee on Nov. 24, 2025, and are being made as an inducement material to each employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

All stock option awards have an exercise price of $79.83 per share, the closing price of PTC's common stock on Nov. 24, 2025, the date of the grant. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the company through the applicable vesting dates. The RSUs each will vest over four years with 25% of the original number of shares vesting on each annual anniversary of the applicable employee's new hire date until fully vested, subject to the employee's continued service with the company through the applicable vesting dates.

ABOUT PTC THERAPEUTICS, INC.
PTC is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow on Facebook, X, and LinkedIn.

For more information please contact:

Investors:
Ellen Cavaleri
+1 (615) 618-8228
ecavaleri@ptcbio.com

Media:
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302629535.html

SOURCE PTC Therapeutics, Inc.

FAQ

What equity awards did PTC Therapeutics (PTCT) grant on Nov. 24, 2025?

PTC granted an aggregate of 2,000 stock options and 8,200 RSUs to 15 new employees as inducement awards.

What is the exercise price and term for PTCT's Nov. 24, 2025 stock options?

The options carry an exercise price of $79.83 and a 10-year term.

How do the PTCT options vest for the Nov. 24, 2025 inducement grants?

Options vest over four years: 25% at the first anniversary of hire, then 6.25% every three months until fully vested.

What is the RSU vesting schedule for PTCT's inducement grants?

Each RSU grant vests over four years with 25% vesting on each annual anniversary of the employee's hire date.

Under what Nasdaq rule were PTC's inducement grants approved?

The grants were made under the Nasdaq Listing Rule 5635(c)(4) inducement grant exception and approved by the Compensation Committee.